Atieh Yaghoubi1,2, Majid Khazaei3, Amir Avan4, Seyed Mahdi Hasanian5, Saman Soleimanpour6,7. 1. Antimicrobial Resistance Research Center, Bu-Ali Research Institute, Mashhad University of Medical Sciences, Mashhad, Iran. 2. Department of Microbiology and Virology, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran. 3. Department of Physiology, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran. 4. Cancer Research Center, Mashhad University of Medical Sciences, Mashhad, Iran. 5. Department of Medical Biochemistry, Faculty of Medicine, Mashhad University of Medical, Sciences, Mashhad, Iran. 6. Antimicrobial Resistance Research Center, Bu-Ali Research Institute, Mashhad University of Medical Sciences, Mashhad, Iran. soleimanpours@mums.ac.ir. 7. Department of Microbiology and Virology, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran. soleimanpours@mums.ac.ir.
Abstract
OBJECTIVE: Colon cancer is a great health concern worldwide, as it is the second leading cause of cancer-related death. Conventional treatment of cancer such as surgery, radiotherapy, and chemotherapy are faced with limitations and side effects. Therefore, strategies for the treatment of cancer need to be modified or new strategies replacing the old one. AIMS: The aim of this study is to review the role of bacteria or their products (such as peptides, bacteriocins, and toxins) as a therapeutic agent for colon cancer. RESULTS AND CONCLUSION: Recently, the therapeutic role of bacteria and their products in colon cancer treatment holds promise as emerging novel anti-cancer agents. Unlike the conventional treatments, targeted therapy based on the use of bacteria that are able to directly target tumor cells without affecting normal cells is evolving as an alternative strategy. Moreover, several bacterial species were used in live, attenuated or genetically modified that are able to multiply selectively in tumors and inhibiting their growth.
OBJECTIVE:Colon cancer is a great health concern worldwide, as it is the second leading cause of cancer-related death. Conventional treatment of cancer such as surgery, radiotherapy, and chemotherapy are faced with limitations and side effects. Therefore, strategies for the treatment of cancer need to be modified or new strategies replacing the old one. AIMS: The aim of this study is to review the role of bacteria or their products (such as peptides, bacteriocins, and toxins) as a therapeutic agent for colon cancer. RESULTS AND CONCLUSION: Recently, the therapeutic role of bacteria and their products in colon cancer treatment holds promise as emerging novel anti-cancer agents. Unlike the conventional treatments, targeted therapy based on the use of bacteria that are able to directly target tumor cells without affecting normal cells is evolving as an alternative strategy. Moreover, several bacterial species were used in live, attenuated or genetically modified that are able to multiply selectively in tumors and inhibiting their growth.
Authors: K Makarova; A Slesarev; Y Wolf; A Sorokin; B Mirkin; E Koonin; A Pavlov; N Pavlova; V Karamychev; N Polouchine; V Shakhova; I Grigoriev; Y Lou; D Rohksar; S Lucas; K Huang; D M Goodstein; T Hawkins; V Plengvidhya; D Welker; J Hughes; Y Goh; A Benson; K Baldwin; J-H Lee; I Díaz-Muñiz; B Dosti; V Smeianov; W Wechter; R Barabote; G Lorca; E Altermann; R Barrangou; B Ganesan; Y Xie; H Rawsthorne; D Tamir; C Parker; F Breidt; J Broadbent; R Hutkins; D O'Sullivan; J Steele; G Unlu; M Saier; T Klaenhammer; P Richardson; S Kozyavkin; B Weimer; D Mills Journal: Proc Natl Acad Sci U S A Date: 2006-10-09 Impact factor: 11.205
Authors: Katarina G Marković; Mirjana Ž Grujović; Maja G Koraćević; Danijela D Nikodijević; Milena G Milutinović; Teresa Semedo-Lemsaddek; Milan D Djilas Journal: Int J Environ Res Public Health Date: 2022-09-19 Impact factor: 4.614